CRISPR Therapeutics AG
| NASDAQ: CRSP | Healthcare / Biotechnology / Switzerland |
| 75.13 | -6.26 | -7.69% | Vol 1.59M | 1Y Perf -40.94% |
| Aug 9th, 2022 16:00 DELAYED |
| BID | 75.00 | ASK | 76.26 | ||
| Open | 78.55 | Previous Close | 81.39 | ||
| Pre-Market | - | After-Market | 75.97 | ||
| - - | 0.84 1.12% |
| Target Price | 116.89 | Analyst Rating | Moderate Buy 1.59 | |
| Potential % | 55.58 | Finscreener Ranking | ★★★★★ 60.36 | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★★★ 63.73 | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★★ 81.33 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 32.58 | Earnings Rating | Strong Sell | |
| Market Cap | 5.86B | Earnings Date | 4th Aug 2022 | |
| Alpha | 0.02 | Standard Deviation | 0.20 | |
| Beta | 1.90 |
Today's Price Range 74.5778.57 | 52W Range 42.51142.64 | 5 Year PE Ratio Range -13.00185.10 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.62% | ||
| 1 Month | 6.11% | ||
| 3 Months | 88.27% | ||
| 6 Months | 25.14% | ||
| 1 Year | -40.94% | ||
| 3 Years | 62.78% | ||
| 5 Years | 363.23% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 2.75 | |||
ROE last 12 Months | 15.78 | |||
ROA (5Y Avg) | 1.05 | |||
ROA last 12 Months | 13.99 | |||
ROC (5Y Avg) | -22.15 | |||
ROC last 12 Months | 14.32 | |||
Return on invested Capital Q | -7.02 | |||
Return on invested Capital Y | -5.29 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 361.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 22.50 | ||||
| 2.88 | ||||
| 442.20 | ||||
| 13.40 | ||||
| -17.70 | ||||
| 6.23 | ||||
| 2.88 | ||||
| 28.98 | ||||
| 4.48B | ||||
| Forward PE | -10.79 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 19.50 | ||||
| 19.90 | ||||
| 0.09 | ||||
| 0.11 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 96.70 | ||||
| 34.10 | ||||
| 36.40 | ||||
| -10 984.70 | ||||
| 34.07 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 13.90M | ||||
| 0.18 | ||||
| 241.09 | ||||
| 74.87 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2022 | -2.23 | -2.40 | -7.62 |
| Q01 2022 | -1.91 | -2.32 | -21.47 |
| Q04 2021 | -1.74 | -1.84 | -5.75 |
| Q03 2021 | -1.69 | -1.67 | 1.18 |
| Q02 2021 | 4.19 | 9.44 | 125.30 |
| Q01 2021 | -1.45 | -1.51 | -4.14 |
| Q04 2020 | -1.23 | -1.50 | -21.95 |
| Q03 2020 | -1.17 | -1.32 | -12.82 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2022 QR | -2.23 | -10.95 | Negative |
| 9/2022 QR | -2.24 | -10.89 | Negative |
| 12/2022 FY | -8.98 | -16.78 | Negative |
| 12/2023 FY | -7.54 | -4.58 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -2.23 |
| Estimates Count | 11 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.59M |
| Shares Outstanding | 78.01K |
| Shares Float | 66.84M |
| Trades Count | 30.25K |
| Dollar Volume | 121.47M |
| Avg. Volume | 1.67M |
| Avg. Weekly Volume | 1.43M |
| Avg. Monthly Volume | 1.58M |
| Avg. Quarterly Volume | 1.99M |
CRISPR Therapeutics AG (NASDAQ: CRSP) stock closed at 81.39 per share at the end of the most recent trading day (a -0.01% change compared to the prior day closing price) with a volume of 1.53M shares and market capitalization of 5.86B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 410 people. CRISPR Therapeutics AG CEO is Samarth Kulkarni.
The one-year performance of CRISPR Therapeutics AG stock is -40.94%, while year-to-date (YTD) performance is 7.4%. CRSP stock has a five-year performance of 363.23%. Its 52-week range is between 42.511 and 142.64, which gives CRSP stock a 52-week price range ratio of 32.58%
CRISPR Therapeutics AG currently has a PE ratio of 22.50, a price-to-book (PB) ratio of 2.88, a price-to-sale (PS) ratio of 442.20, a price to cashflow ratio of 13.40, a PEG ratio of 2.32, a ROA of 13.99%, a ROC of 14.32% and a ROE of 15.78%. The company’s profit margin is 34.07%, its EBITDA margin is 36.40%, and its revenue ttm is $13.90 Million , which makes it $0.18 revenue per share.
Of the last four earnings reports from CRISPR Therapeutics AG, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.23 for the next earnings report. CRISPR Therapeutics AG’s next earnings report date is -.
The consensus rating of Wall Street analysts for CRISPR Therapeutics AG is Moderate Buy (1.59), with a target price of $116.89, which is +55.58% compared to the current price. The earnings rating for CRISPR Therapeutics AG stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CRISPR Therapeutics AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CRISPR Therapeutics AG has a Buy technical analysis rating based on Technical Indicators (ADX : 24.23, ATR14 : 5.38, CCI20 : 87.77, Chaikin Money Flow : 0.11, MACD : 2.41, Money Flow Index : 54.07, ROC : 1.80, RSI : 42.98, STOCH (14,3) : 60.96, STOCH RSI : 1.00, UO : 55.06, Williams %R : -39.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CRISPR Therapeutics AG in the last 12-months were: James R. Kasinger (Option Excercise at a value of $0), Lawrence Otto Klein (Option Excercise at a value of $0), Samarth Kulkarni (Option Excercise at a value of $91 858), Tony W. Ho (Option Excercise at a value of $0)
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.
CEO: Samarth Kulkarni
Telephone: +41 415613277
Address: Baarerstrasse 14, Zug 6300, , CH
Number of employees: 410
TipRanks News for CRSP
Tue, 09 Aug 2022 13:30 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Crispr Therapeutics AG (CRSP) and Annovis Bio (ANVS)
- TipRanks. All rights reserved.Tue, 09 Aug 2022 04:50 GMT Analysts Offer Insights on Healthcare Companies: Prothena (PRTA), Crispr Therapeutics AG (CRSP) and SI-Bone (SIBN)
- TipRanks. All rights reserved.Thu, 28 Jul 2022 03:26 GMT CRISPR Therapeutics: Why Its Growth Potential Could Get Cheaper
- TipRanks. All rights reserved.Tue, 12 Jul 2022 12:45 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from William Blair
- TipRanks. All rights reserved.Tue, 12 Jul 2022 04:16 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from JMP Securities
- TipRanks. All rights reserved.Mon, 27 Jun 2022 14:56 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from William Blair
- TipRanks. All rights reserved.Thu, 23 Jun 2022 14:15 GMT Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Cullinan Management (CGEM)
- TipRanks. All rights reserved.Mon, 13 Jun 2022 12:15 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Chardan Capital
- TipRanks. All rights reserved.Mon, 13 Jun 2022 10:35 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from Needham
- TipRanks. All rights reserved.Mon, 13 Jun 2022 04:15 GMT Crispr Therapeutics AG (CRSP) Gets a Buy Rating from JMP Securities
- TipRanks. All rights reserved.Wed, 11 May 2022 16:40 GMT Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Crispr Therapeutics AG (CRSP) and Biohaven Pharmaceutical Holding Co (BHVN)
- TipRanks. All rights reserved.Wed, 11 May 2022 04:45 GMT Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Crispr Therapeutics AG (CRSP) and TELA Bio (TELA)
- TipRanks. All rights reserved.Wed, 13 Apr 2022 09:35 GMT Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Crispr Therapeutics AG (CRSP) and Precision BioSciences (DTIL)
- TipRanks. All rights reserved.Fri, 08 Apr 2022 19:55 GMT Crispr Therapeutics AG (CRSP) Receives a Buy from Brookline Capital Markets
- TipRanks. All rights reserved.Tue, 01 Mar 2022 05:35 GMT Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row
- TipRanks. All rights reserved.Wed, 16 Feb 2022 12:40 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Crispr Therapeutics AG (CRSP) and Allakos (ALLK)
- TipRanks. All rights reserved.Wed, 16 Feb 2022 05:35 GMT Analysts Offer Insights on Healthcare Companies: Seagen (SGEN), Crispr Therapeutics AG (CRSP) and Hookipa Pharma (HOOK)
- TipRanks. All rights reserved.Fri, 11 Feb 2022 05:25 GMT Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Deciphera Pharmaceuticals (DCPH)
- TipRanks. All rights reserved.Sun, 09 Jan 2022 09:31 GMT CRSP: Investors Pumped by Unique Price Point, Intriguing Pipeline
- TipRanks. All rights reserved.
